CURE Pharmaceutical (OTCQB: CURR), based in Oxnard, CA, is a vertically integrated delivery and development company committed to improving efficacy, safety, and patient experience through its proprietary dosage forms and delivery systems. CURR has an FDA- and DEA- registered, GMP manufacturing facility and is a pioneering developer of CUREform™, a patented delivery platform. CUREform™ includes CUREfilm®, one of the most advanced oral thin films on the market today; microCURE™, an innovative emulsion technology utilizing proprietary encapsulation techniques; and CUREpods™ a novel chewable delivery system.
CURR names Canopy Rivers Chairman John K. Bell, FCA, FCPA, ICD.D to its board of directors.
Bell brings more than 40 years of experience to the company, most recently serving as chairman of the Canopy Rivers board of directors and former chairman of Canopy Growth’s board of directors
CURR offers combined technologies that provide opportunities for both immediate and controlled-release delivery of a wide range of active ingredients. CURR partners with biotech, pharmaceutical, and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, with partnerships in the U.S.A, Canada, Israel, and other markets. The CURR company mission is to improve people’s lives by redefining how medicines are delivered and experienced.
CURR Products Fall Into Two Categories: Nutraceuticals (dietary supplements) and Pharmaceutical
CUREfilm® Sleep is a daily dietary supplement that delivers a unique blend of five active ingredients with the CUREfilm® platform to promote healthy sleep patterns. This product is launched in U.S. markets.
CUREfilm® D is a high-potency dietary supplement that provides 50,000 IU of Vitamin D3
CUREfilm® β-Caryophyllene is a dietary supplement that contains 30mg of β-Caryophyllene, a powerful terpene known for its anti-inflammatory and analgesic properties.
CUREfilm® Blue contains 50mg of Sildenafil delivered with the CUREfilm® platform.
CURR Expands to Europe, Signs Licensing Agreement with ReLeaf Europe to Provide Advanced Cannabinoid Delivery
CURRhas signed a licensing and collaboration agreement with Vanguard Scientific Systems, Inc.
Vanguard is a premier provider of equipment, systems and performance solutions servicing the botanical extraction industry, including the MIDAS XII, a next-generation GMP compliant supercritical CO2 extraction technology, as well as industrially scaled CO2 facility solutions. The license gives Vanguard the right to practice CURE’s patented extraction methods, providing customer confidence in choosing Vanguard’s portfolio of extraction manufacturers
The industry is poised to grow to $2.1 billion in 2020, a 700% increase from 2016. CURR is strategically positioned with multiple high value assets and extremely well-placed marketing partners to optimize the company’s earnings potential in the growing fields of key supply and delivery solutions, including the multi-billion-dollar marketplace.
For more information on CURE Pharmaceutical(OTCQB: CURR) visit: https://medium.com/@smallcap/cure-pharmaceutical-otcqb-curr-is-a-vertically-integrated-drug-delivery-and-development-company-7d618bfa298e
Company Name: Cure Pharmaceuticals, Inc.
Contact Person: Media Relations
Email: Send Email
Phone: (805) 824-0410
Address:1620 Beacon Place
State: CA 93033
Country: United States